CN107929420B - 改善人体气血功能和提高免疫力的中药组合物和检测方法 - Google Patents
改善人体气血功能和提高免疫力的中药组合物和检测方法 Download PDFInfo
- Publication number
- CN107929420B CN107929420B CN201711186119.2A CN201711186119A CN107929420B CN 107929420 B CN107929420 B CN 107929420B CN 201711186119 A CN201711186119 A CN 201711186119A CN 107929420 B CN107929420 B CN 107929420B
- Authority
- CN
- China
- Prior art keywords
- blood
- weight
- purified water
- parts
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 118
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 230000036039 immunity Effects 0.000 title claims abstract description 19
- 230000000157 blood function Effects 0.000 title claims abstract description 15
- 238000001514 detection method Methods 0.000 title abstract description 7
- 108010010803 Gelatin Proteins 0.000 claims abstract description 70
- 239000008273 gelatin Substances 0.000 claims abstract description 70
- 229920000159 gelatin Polymers 0.000 claims abstract description 70
- 235000019322 gelatine Nutrition 0.000 claims abstract description 70
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 70
- 235000006533 astragalus Nutrition 0.000 claims abstract description 60
- 241000405414 Rehmannia Species 0.000 claims abstract description 55
- 235000013924 ferrous gluconate Nutrition 0.000 claims abstract description 50
- 239000004222 ferrous gluconate Substances 0.000 claims abstract description 50
- 229960001645 ferrous gluconate Drugs 0.000 claims abstract description 50
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims abstract description 50
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 36
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 30
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 15
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 176
- 239000007788 liquid Substances 0.000 claims description 120
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 105
- 239000008213 purified water Substances 0.000 claims description 88
- 239000000706 filtrate Substances 0.000 claims description 82
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 62
- 238000001914 filtration Methods 0.000 claims description 62
- 238000002156 mixing Methods 0.000 claims description 52
- 230000002829 reductive effect Effects 0.000 claims description 51
- 241001061264 Astragalus Species 0.000 claims description 43
- 210000004233 talus Anatomy 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 35
- 241000756943 Codonopsis Species 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 29
- 229940107666 astragalus root Drugs 0.000 claims description 26
- 238000010438 heat treatment Methods 0.000 claims description 26
- 239000009636 Huang Qi Substances 0.000 claims description 22
- 239000000796 flavoring agent Substances 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 21
- 108010052008 colla corii asini Proteins 0.000 claims description 19
- 235000013355 food flavoring agent Nutrition 0.000 claims description 18
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 15
- 239000001509 sodium citrate Substances 0.000 claims description 15
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 15
- 239000000600 sorbitol Substances 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 13
- 238000004806 packaging method and process Methods 0.000 claims description 13
- 230000001376 precipitating effect Effects 0.000 claims description 13
- 238000007789 sealing Methods 0.000 claims description 13
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 5
- 108010011485 Aspartame Proteins 0.000 claims description 5
- 239000000605 aspartame Substances 0.000 claims description 5
- 235000010357 aspartame Nutrition 0.000 claims description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 5
- 229960003438 aspartame Drugs 0.000 claims description 5
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 3
- 229940085605 saccharin sodium Drugs 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 241000125175 Angelica Species 0.000 claims 1
- 235000010358 acesulfame potassium Nutrition 0.000 claims 1
- 229960004998 acesulfame potassium Drugs 0.000 claims 1
- 239000000619 acesulfame-K Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 85
- 238000002360 preparation method Methods 0.000 abstract description 34
- 239000008280 blood Substances 0.000 description 124
- 210000004369 blood Anatomy 0.000 description 123
- 244000061520 Angelica archangelica Species 0.000 description 61
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 53
- 230000007812 deficiency Effects 0.000 description 44
- 230000006870 function Effects 0.000 description 36
- 210000000952 spleen Anatomy 0.000 description 34
- 229910052742 iron Inorganic materials 0.000 description 26
- 208000007502 anemia Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 208000031971 Yin Deficiency Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 108010054147 Hemoglobins Proteins 0.000 description 16
- 102000001554 Hemoglobins Human genes 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 16
- 230000009471 action Effects 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- -1 calycosin glucoside Chemical class 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 235000009508 confectionery Nutrition 0.000 description 13
- 235000021552 granulated sugar Nutrition 0.000 description 13
- 208000036654 deficiency anemia Diseases 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 8
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229960002478 aldosterone Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 206010016256 fatigue Diseases 0.000 description 8
- 235000003599 food sweetener Nutrition 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000003765 sweetening agent Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N Calycosin Natural products C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 7
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 7
- 208000019255 Menstrual disease Diseases 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 230000009102 absorption Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 208000034158 bleeding Diseases 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 229930182478 glucoside Natural products 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 230000005906 menstruation Effects 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 206010027514 Metrorrhagia Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 206010033557 Palpitations Diseases 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 208000018706 hematopoietic system disease Diseases 0.000 description 6
- 235000008216 herbs Nutrition 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002633 protecting effect Effects 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 206010022971 Iron Deficiencies Diseases 0.000 description 5
- 241000405911 Rehmannia glutinosa Species 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 208000014951 hematologic disease Diseases 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000001502 supplementing effect Effects 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- 208000019838 Blood disease Diseases 0.000 description 4
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 102000008857 Ferritin Human genes 0.000 description 4
- 108050000784 Ferritin Proteins 0.000 description 4
- 238000008416 Ferritin Methods 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 240000005373 Panax quinquefolius Species 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 206010029410 night sweats Diseases 0.000 description 4
- 230000036565 night sweats Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 230000010415 tropism Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 208000010445 Chilblains Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 3
- 208000034507 Haematemesis Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102100030856 Myoglobin Human genes 0.000 description 3
- 108010062374 Myoglobin Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000132012 Atractylodes Species 0.000 description 2
- 241000269417 Bufo Species 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 241000208671 Campanulaceae Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 240000001008 Dimocarpus longan Species 0.000 description 2
- 235000000235 Euphoria longan Nutrition 0.000 description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 244000236658 Paeonia lactiflora Species 0.000 description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 2
- 241000013557 Plantaginaceae Species 0.000 description 2
- 206010038084 Rectocele Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 2
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229950005197 butylphthalide Drugs 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 2
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 210000003013 erythroid precursor cell Anatomy 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000007106 menorrhagia Diseases 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000003446 pia mater Anatomy 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- JZLOKWGVGHYBKD-UHFFFAOYSA-M sodium;2-acetyloxybenzoate Chemical compound [Na+].CC(=O)OC1=CC=CC=C1C([O-])=O JZLOKWGVGHYBKD-UHFFFAOYSA-M 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- NYCXYIWXBJWWIL-PZYDOOQISA-N (2s,3r,4s,5s,6r)-2-[[(1as,1bs,2s,5ar,6s,6as)-6-hydroxy-1a-(hydroxymethyl)-2,4,5,5a,6,6a-hexahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-2-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2CCO1 NYCXYIWXBJWWIL-PZYDOOQISA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 1
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241001550206 Colla Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 229930195236 Digitoside Natural products 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000207934 Eriodictyon Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000985610 Forpus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 241000931143 Gleditsia sinensis Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 239000009220 Liuwei Dihuang Decoction Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000283966 Pholidota <mammal> Species 0.000 description 1
- 241001482237 Pica Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000008619 Xingren Substances 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000007215 black sesame Nutrition 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NYCXYIWXBJWWIL-UHFFFAOYSA-N dihydrocatalpol Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2CCO1 NYCXYIWXBJWWIL-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000000214 effect on organisms Effects 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IIGUXNQRQSATOU-UHFFFAOYSA-N ethyl 2-[methyl(nitroso)amino]acetate Chemical compound CCOC(=O)CN(C)N=O IIGUXNQRQSATOU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 108091005655 heme enzymes Proteins 0.000 description 1
- 102000035124 heme enzymes Human genes 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- APVZWAOKZPNDNR-UHFFFAOYSA-L iron(ii) citrate Chemical compound [Fe+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O APVZWAOKZPNDNR-UHFFFAOYSA-L 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 210000001369 pituitary-adrenal system Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NCTHNHPAQAVBEB-WGCWOXMQSA-M sodium ferulate Chemical compound [Na+].COC1=CC(\C=C\C([O-])=O)=CC=C1O NCTHNHPAQAVBEB-WGCWOXMQSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- KDSWDGKIENPKLB-QJDQKFITSA-N verbascoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)CCC=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O KDSWDGKIENPKLB-QJDQKFITSA-N 0.000 description 1
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/89—Inverse chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及改善人体气血功能和提高免疫力的中药组合物和检测方法。具体的说,一方面,本发明涉及一种中药组合物,其由黄芪1200重量份、当归400~600重量份、熟地黄300~500重量份、党参300~500重量份、阿胶100~300重量份、葡萄糖酸亚铁20~40重量份以及任选的药用辅料制成。还涉及该中药组合物的制备方法和检测方法。本发明中药组合物能够改善人体气血功能和提高免疫力,并且呈现如说明书所述优异技术效果。
Description
技术领域
本发明属于医药健康产品领域,涉及一种用于改善人体气血功能和提高免疫力的中药组合物,还涉及该中药组合物的制备工艺以及其检测方法,特别是涉及一种用于改善人体气血功能和提高免疫力的可称之为海瑞康牌黄芪当归阿胶口服液的中药组合物,以及它们的制备方法以及其检测方法。
背景技术
营养性贫血分为小细胞性贫血和大细胞性贫血两种。前者也叫缺铁性贫血,多发于婴儿、儿童;后者又叫巨幼红细胞性贫血,其病因是使红细胞成熟的因素缺乏而发病。
中医学把营养性贫血归属“血虚”、“虚劳”所致范畴,认为血液来源于脾,根本在肾并涉及心、肝两脏,如果脾胃虚弱,不能医化水谷精微,气血生化之源不足,产生贫血。而补血剂是以《内经》“虚则补之,损则益之”等理论为依据组方配伍的一类方剂。因此,方中常配伍补气药,以奏补气生血之功。诚如《温病条辨治血论》所谓:“血虚者,补其气而血自生”。肾藏精,精生髓,髓生血,故有“血之源头在于肾”之说。海瑞康牌血尔红口服液是以黄芪、当归、熟地黄、党参、阿胶、葡萄糖酸亚铁为原料制成的保健食品,经功能试验证明,具有改善营养性贫血的保健功能。
贫血是我国居民中比较常见的一种疾病,也是一种全球性的疾病,贫血侵袭的对象也最为广泛,包括儿童、青少年、还有成年男女,尤其是孕妇和乳母及儿童。营养性贫血的主要的六大表现:①起病缓慢,一般先是发现皮肤黏膜逐渐苍白,尤其以口唇和甲床最明显;②疲乏无力,不爱活动,常有烦躁不安或者萎靡不振;③食欲减退,常有呕吐或腹泻,有的儿童会出现异食癖;④医生检查时会发现儿童的肝脾肿大,心率增快,化验检查以血红蛋白减少为主;⑤患者外表多为虚胖,头发稀疏发黄,面色苍黄,疲乏无力,食欲不振;⑥智力和动作的发育都较落后,甚至逐渐退步。
营养性贫血是全世界发病率最高的营养缺乏疾病之一,据世界卫生组织(WTO)对世界人口50亿中就患营养性贫血的调查,全世界约有10~30%的人群有不同程度的缺铁即有10亿人。在我国的发病率也是非常高的,《2004年中国居民营养与健康状况》披露,我国居民因缺铁患贫血病率平均为13.6%;两岁以内婴幼儿、60岁以上的老人、育龄妇女贫血患病率分别为21.7%、18.5%、20.6%;另一组是由于铁营养缺乏,中国缺铁性贫血发生率达到15~20%,妇女儿童贫血率高达20%,缺铁被世界卫生组织(WTO)列为世界四大营养素缺乏症之一。因此,补血产品市场需求量大。
另外,众所周知的,通过服用补血产品还可以使人体的免疫力得到提高。
从目前市场补血产品情况来看,补血产品主要成分为两类:一类为乳酸亚铁、卟啉铁、硫酸亚铁、柠檬酸亚铁、葡萄糖亚铁、Vc等化学合成成分;另一类是为阿胶、蜂蜜、乌鸡、枸杞、大豆磷脂、人参、当归、黄芪等动植物和中草药成分。然而市面上尚未见有将化学合成成分和动植物及中草药成分组合来实现补血的产品。
因此,本领域仍然期待有新的补血产品和补血方法,特别是例如通过将化学合成成分和动植物及中草药成分组合来实现补血的产品以及实现补血的方法;此外,基于这种通过服用补血产品的方式,以期改善人体气血功能和提高免疫力,亦是本领域技术人员迫切期待的。
发明内容
本发明的目的在于提供一种补血产品和补血方法,以期改善人体气血功能和提高免疫力。已经出人意料的发现,本发明提供的可以用于改善人体气血功能和提高免疫力的可称之为海瑞康牌黄芪当归阿胶口服液的中药组合物呈现优异的技术效果。本发明基于此发现而得以完成。
第一方面,本发明提供了一种中药组合物,其由黄芪、当归、熟地黄、党参、阿胶、葡萄糖酸亚铁以及任选的药用辅料制成。
根据本发明第一方面的中药组合物,其由黄芪1200重量份、当归400~600重量份、熟地黄300~500重量份、党参300~500重量份、阿胶100~300重量份、葡萄糖酸亚铁20~40重量份以及任选的药用辅料制成。
根据本发明第一方面的中药组合物,其由黄芪1200重量份、当归450~550重量份、熟地黄350~450重量份、党参350~450重量份、阿胶150~250重量份、葡萄糖酸亚铁25~35重量份以及任选的药用辅料制成。
根据本发明第一方面的中药组合物,其由黄芪1200重量份、当归500重量份、熟地黄400重量份、党参400重量份、阿胶200重量份、葡萄糖酸亚铁32重量份以及任选的药用辅料制成。
根据本发明第一方面的中药组合物,其为口服液形式的液体药剂。
根据本发明第一方面的中药组合物,其为口服液形式的液体药剂,其制备每100ml使用的黄芪药材量为8~16g。
根据本发明第一方面的中药组合物,其为口服液形式的液体药剂,其制备每100ml使用的黄芪药材量为10~14g。
根据本发明第一方面的中药组合物,其为口服液形式的液体药剂,其制备每100ml使用的黄芪药材量为12g。
根据本发明第一方面的中药组合物,其中所述药用辅料包括调味剂。在一个实施方案中,所述的调味剂是甜味剂,例如阿司巴坦、安赛蜜、糖精钠、蔗糖(例如白砂糖)等。这些甜味剂的用量根据其具体使用品种以及本领域技术人员的经验可以容易的确定,例如阿司巴坦、安赛蜜、糖精钠等的量通常为0.05%~1%,特别是例如0.1%,例如蔗糖(例如白砂糖)可以占本发明中药组合物重量的5~25%,例如10~20%,例如10%、12%、15%、20%。特别是还可以根据不同使用人群的偏好等因素决定甜味剂的用量以获得产品的期待甜度,这种甜味剂用量的选择是本领域技术人员公知的,而且它们的种类和用量并不会影响产品的理化性质。
根据本发明第一方面的中药组合物,其为口服液形式的液体药剂,其由包括如下步骤的方法制得:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次(例如,第一次加5~8倍例如6倍量的纯化水煎煮1~3h例如2h,过滤,得滤液;第二次滤渣加5~8倍例如6倍量的纯化水煎煮1~3h例如2h,过滤,得滤液),合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比0.8~1.2:1例如1:1;加入乙醇(例如浓度大于等于90%或者大于等于95%的乙醇)使含醇量达55~65%(例如至含醇量达60%),静置醇沉20~30小时,取上清液,过滤,得滤液;
(3)将步骤(2)所得滤液在60~80℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08(测量温度40℃),得中药提取液,备用;
(4)将阿胶捣成小碎块,加8~12倍量例如10倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和任选的调味剂(例如蔗糖)合并,加2~4倍量例如3倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌(例如105℃灭菌45min),即得。
根据本发明第一方面的中药组合物,其中所述药用辅料还包括枸橼酸钠和山梨醇。在一个实施方案中,药材黄芪和枸橼酸钠的重量比为12:0.1。在一个实施方案中,药材黄芪和山梨醇的重量比为12:0.5。在一个实施方案中,枸橼酸钠和山梨醇是在步骤(2)所得滤液中添加的。
进一步的,本发明第二方面提供了制备中药组合物例如本发明第一方面任一实施方案所述中药组合物的方法,所述中药组合物由黄芪、当归、熟地黄、党参、阿胶、葡萄糖酸亚铁以及任选的药用辅料制成;该方法包括如下步骤:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次(例如,第一次加5~8倍例如6倍量的纯化水煎煮1~3h例如2h,过滤,得滤液;第二次滤渣加5~8倍例如6倍量的纯化水煎煮1~3h例如2h,过滤,得滤液),合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比0.8~1.2:1例如1:1;加入乙醇(例如浓度大于等于90%或者大于等于95%的乙醇)使含醇量达55~65%(例如至含醇量达60%),静置醇沉20~30小时,取上清液,过滤,得滤液;
(3)将步骤(2)所得滤液在60~80℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08(测量温度40℃),得中药提取液,备用;
(4)将阿胶捣成小碎块,加8~12倍量例如10倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和任选的调味剂(例如蔗糖)合并,加2~4倍量例如3倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌(例如105℃灭菌45min),即得。
根据本发明第二方面的方法,所述中药组合物由黄芪1200重量份、当归400~600重量份、熟地黄300~500重量份、党参300~500重量份、阿胶100~300重量份、葡萄糖酸亚铁20~40重量份以及任选的药用辅料制成。
根据本发明第二方面的方法,所述中药组合物由黄芪1200重量份、当归450~550重量份、熟地黄350~450重量份、党参350~450重量份、阿胶150~250重量份、葡萄糖酸亚铁25~35重量份以及任选的药用辅料制成。
根据本发明第二方面的方法,所述中药组合物由黄芪1200重量份、当归500重量份、熟地黄400重量份、党参400重量份、阿胶200重量份、葡萄糖酸亚铁32重量份以及任选的药用辅料制成。
根据本发明第二方面的方法,所述中药组合物为口服液形式的液体药剂。
根据本发明第二方面的方法,所述中药组合物为口服液形式的液体药剂,其制备每100ml使用的黄芪药材量为8~16g。
根据本发明第二方面的方法,所述中药组合物为口服液形式的液体药剂,其制备每100ml使用的黄芪药材量为10~14g。
根据本发明第二方面的方法,所述中药组合物为口服液形式的液体药剂,其制备每100ml使用的黄芪药材量为12g。
根据本发明第二方面的方法,所述药用辅料包括调味剂。在一个实施方案中,所述的调味剂是甜味剂,例如阿司巴坦、安赛蜜、糖精钠、蔗糖(例如白砂糖)等。这些甜味剂的用量根据其具体使用品种以及本领域技术人员的经验可以容易的确定,例如阿司巴坦、安赛蜜、糖精钠等的量通常为0.05%~1%,特别是例如0.1%,例如蔗糖(例如白砂糖)可以占本发明中药组合物重量的5~25%,例如10~20%,例如10%、12%、15%、20%。特别是还可以根据不同使用人群的偏好等因素决定甜味剂的用量以获得产品的期待甜度,这种甜味剂用量的选择是本领域技术人员公知的,而且它们的种类和用量并不会影响产品的理化性质。
根据本发明第二方面的方法,所述药用辅料还包括枸橼酸钠和山梨醇。在一个实施方案中,药材黄芪和枸橼酸钠的重量比为12:0.1。在一个实施方案中,药材黄芪和山梨醇的重量比为12:0.5。在一个实施方案中,枸橼酸钠和山梨醇是在步骤(2)所得滤液中添加的。
进一步的,本发明第三方面提供了本发明第一方面任一实施方案所述中药组合物或者本发明第二方面任一实施方案所述方法制得的中药组合物在制备用于改善人体气血功能和提高免疫力的产品中的用途。
进一步的,本发明第四方面提供了使用反相高效液相色谱法测定本发明第一方面任一实施方案所述中药组合物或者本发明第二方面任一实施方案所述方法制得的中药组合物中毛蕊异黄酮葡萄糖苷的含量的方法,所述反相高效液相色谱法采用Kromasil C18柱(4.6mm×200mm,5μm),流动相为乙腈-水(28:72),流速为1.0mL/min,检测波长为267nm。
根据本发明任一方面的任一实施方案,其中所述中药组合物具有如本发明任一实施例中任一项所述的配方。
根据本发明任一方面的任一实施方案,其中所中药组合物具有如本发明任一实施例中任一项所述的配方和制法。
在本发明上述制备方法的步骤中,虽然其描述的具体步骤在某些细节上或者语言描述上与下文具体实施方式部分的制备例中所描述的步骤有所区别,然而,本领域技术人员根据本发明全文的详细公开完全可以概括出以上所述方法步骤。
本发明的任一方面的任一实施方案,可以与其它实施方案进行组合,只要它们不会出现矛盾。此外,在本发明任一方面的任一实施方案中,任一技术特征可以适用于其它实施方案中的该技术特征,只要它们不会出现矛盾。下面对本发明作进一步的描述。
本发明所引述的所有文献,它们的全部内容通过引用并入本文,并且如果这些文献所表达的含义与本发明不一致时,以本发明的表述为准。此外,本发明使用的各种术语和短语具有本领域技术人员公知的一般含义,即便如此,本发明仍然希望在此对这些术语和短语作更详尽的说明和解释,提及的术语和短语如有与公知含义不一致的,以本发明所表述的含义为准。
本发明的中药组合物采用黄芪、当归、熟地黄、党参、阿胶、葡萄糖酸亚铁制成。
黄芪(Astragalus membranaceus(Fisch.)Bunge.),又名绵芪。主根肥厚,木质,常分枝,灰白色。茎直立,上部多分枝,有细棱,被白色柔毛。多年生草本,高50-100厘米。产于内蒙古、山西、甘肃、黑龙江等地,为国家三级保护植物。黄芪的药用迄今已有2000多年的历史,其有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。但表实邪盛,气滞湿阻,食积停滞,痈疽初期或溃后热毒尚盛等实证,以及阴虚阳亢者,均须禁服。由于长期大量采挖,近几年来野生黄芪的数量急剧减少,有趋于绝灭的危险。为此确定该植物为渐危种,国家三级保护植物。
黄芪性甘,味温,归肺、脾、肝、肾经。
黄芪的药用价值包括:1、表虚自汗:多用于体虚表弱所致的自汗。如表气不固,而汗出,用黄芪配白术、防风治之,久服必效。方如玉屏风散;也可配浮小麦、麻黄根等。2、阴虚盗汗:可与生地、麦冬等滋阴药同用。3、急性肾炎水肿:用于阳气不足所致的虚性水肿,并常与防已、茯苓、白术等合而用,方如防己黄芪汤。4、慢性肾炎水肿、脾肾虚:常与党参、白术、茯苓同用。5、阳气虚弱:用于疮疡久不溃破而内陷,有促进溃破及局限作用。痈疽久不穿头,常与穿山甲、皂角刺、当归、川芎同用。6、疮疡溃破:久不收口,有生肌收口之作用,常配银花、皂刺、地丁等。脓液清洗,与党参、肉桂等同用。7、肺气虚证:咳喘日久,气短神疲,痰雍于肺无力咯出。常配伍紫菀、款冬等,温肺定喘,健肺气之品。脾生痰,肺储痰,所以健太阴以祛痰,黄芪补气所以尤善治气虚。8、气虚衰弱:倦怠乏力,或中气下陷、脱肛、子宫脱垂。补气健脾,常与党参、白术等配伍;用于益气升阳而举陷,常与党参、升麻、柴胡、炙甘草等合用。
临床上应用于:1、高血压病;2、缺血性心脏病;3、急性肾小球肾炎;4、幽门螺旋杆菌阳性胃溃疡;5、银屑病;6、糖尿病;7、慢性鼻炎;8、骨质疏松。
黄芪是百姓经常食用的纯天然品,民间流传着“常喝黄芪汤,防病保健康”的顺口溜,意思是说经常用黄芪同琼珍灵芝煎汤或泡水代茶饮,具有良好的防病保健作用。黄芪和人参均属补气良药,人参偏重于大补元气,回阳救逆,常用于虚脱、休克等急症,效果较好。而黄芪则以补虚为主,常用于体衰日久、言语低弱、脉细无力者。有些人一遇天气变化就容易感冒,中医称为“表不固”,可用黄芪来固表,常服黄芪可以避免经常性的感冒。
现代医学研究表明,黄芪有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。能消除实验性肾炎蛋白尿,增强心肌收缩力,调节血糖含量。黄芪不仅能扩张冠状动脉,改善心肌供血,提高免疫功能,而且能够延缓细胞衰老的进程。黄芪食用方便,可煎汤,煎膏,浸酒,入菜肴等。
黄芪具有补气及补气生津、补气生血之功效,且常相须为用,能相互增强疗效。但人参作用较强,被誉为补气第一要药,并具有益气救脱、安神增智、补气助阳之功。党参补气之力较为平和,专于补益脾肺之气,兼能补血。黄芪补益元气之力不及人参,但长于补气升阳、益卫固表、托疮生肌、利水退肿,尤宜于脾虚气陷及表虚自汗等证。
黄芪的化学成分方面,主要含苷类、多糖、黄酮、氨基酸、微量元素等。
熟地黄,原名:地黄,又名:怀庆地黄、熟地。拉丁文名:Rehmannia glutinosa(Gaetn.)Libosch.ex Fisch.et Mey.玄参科、地黄属植物,密被灰白色多细胞长柔毛和腺毛。根茎药用。中药材熟地黄为生地黄的炮制加工品,其表面乌黑有光泽,质软而柔韧,味甘,性微温,具有滋阴补血、益精填髓等功效。主治肝肾阴虚、腰膝酸软、骨蒸潮热、盗汗遗精、内热消渴、血虚萎黄、心悸怔忡、月经不调、眩晕耳鸣、须发早白等症。生地黄熏蒸至黑润,为熟地黄,该品为不规则块状,大小不一,内外均是漆黑色,有光泽,外表面皱缩不平。断面滋润,中心部可见光亮的油脂状块,粘性大,质柔软,气微,味甜。经过九蒸九晒,以块根肥大,软润,内外乌黑有光泽者为佳。
性味归经方面。味甘;性温。归肝;肾经。功效主治:补血滋润;益精填髓;用于血虚萎黄;眩晕心悸;月经不调;崩不止;肝肾阴亏;潮热盗汗;遗精阳痿;不育不孕;月经不调;崩漏下血;腰膝酸软;耳鸣耳聋;头目昏花;须发早白;消渴;便秘;肾虚喘促。
地黄具有广泛的药理作用。关于熟地黄和生地黄对血管内血栓形成综合征作用的药效比较表明:中国产的猪胆状的粗熟地黄能够强烈抑制肝脏出血性坏死灶及单纯性坏死。而熟地黄抗凝血酶的作用较弱。应用纤维蛋白平板法通过纤维蛋白溶酶原激活作用探讨对纤溶系统的活化作用,发现熟地具有活化作用,而生地黄无此作用。亦有报告认为,地黄炒炭前后均有止血作用,且地黄制炭后止血作用并未增强。对生地黄、熟地黄、生地炭、熟地炭的水煎液止血效果进行分析,结果无显著性差异。实验发现:怀庆熟地黄水煎剂灌服,能使甲亢型阴虚大鼠的体重减轻得以缓解,24小时饮水量及尿量明显减少,血浆T3、T4浓度水平有显著改善(即T3降低、T4升高)及AD(血浆中醛固酮)水平明显升高。证明其确有较强的滋阴作用。并初步认为,熟地滋阴补肾的作用与改善体内AD水平有关。
熟地黄水煎剂给小鼠灌服,可明显增高动物血清中谷胱甘肽过氧化物酶(GSH-Px)的活性;降低血清中过氧化脂质的含量。可使血中超氧化物歧化酶(SOD)的活性有一定程度的升高,但无统计学的意义。对血中过氧化氢酶活性无影响。熟地黄对大鼠部分脏器蛋白质代谢有一定作用。熟地黄口服具有抑制上皮细胞有丝分裂的作用。实验表明:以熟地黄为主药的六味地黄汤对正常小鼠除可增加体重、延长游泳时间外、增强体力外,还能降低N-亚硝基肌氨酸乙酯引起的小鼠前胃鳞癌的诱发率,使接受化学致癌物的动物脾脏淋巴小结生发中心增生活跃,在接种移植性肿瘤的初期可增强单核巨噬系统的吞噬活性,提高荷瘤动物血中白蛋白和球蛋白的比例,似可延长荷瘤动物的存活时间。⑴熟地黄延缓小鼠衰老的作用:熟地黄20%水煎液每日灌胃0.3ml共45天,处死取血,测定超氧化物歧化酶(SOD)、过氧化氢酶(CAT)、谷胱甘肽过氧化物酶(GSH-Px)活力和过氧化脂质(LPO)的含量。结果熟地黄可增强GSH-Px活性和降低血清中LPO的含量,与对照组相比较分别为P<0.05和P<0.01。⑵对甲亢型阴虚大鼠的影响:用三碘甲腺原氨酸(T3)给予大鼠造成阴虚模型并给于熟地黄水煎液3ml(70%浓度),共6天,然后测定各数据。结果正常对照组与给药组相比,用药前后无论是体征、体重改变、24小时饮水量与尿量以及各相关激素:T3、甲状腺素(T4)和醛固酮(AD)的血浆浓度均无显著差异(P>0.05)。但造模以后,阴虚组和正常组相比,则有非常显著变化,如兴奋好斗,体重减轻,24小时饮水量及饮量增加,T3浓度升高,T4、AD浓度降低等。而阴虚大鼠给以熟地黄后上述症状及各项指标均显著改善,趋于正常(和阴虚组相比)。如阴虚加熟地黄组和阴虚组相比,血浆AD浓度显著升高(P<0.05),24小时尿量显著减少(P<0.01),提示熟地黄具有滋补肾阴的作用与改善体内AD水平有关。阴虚给药组血浆中T3、T4浓度明显改善(T3浓度降低,T4浓度升高),并趋于正常。表明熟地黄不仅能通过对全身性的调节作用,改善阴虚症状,并能对异常的甲状腺素状态起调节作用。另外阴虚给药组和正常组相比,在体重改变、24小时饮水量、血浆T3、T4浓度等方面,仍显著未达到正常水平,均有极显著差异(P<0.01)。这表明,虽然阴虚给药组和阴虚组相比,各项指标均有显著改善并趋于正常,但未完全恢复到正常。说明熟地黄的作用还是有局限性。⑶熟地黄补血作用的实验观察:生、熟怀地黄制成1:1水煎剂灌胃给于小鼠观察对失血性贫血、造血干细胞和骨髓红系造血祖细胞CFU-E生成的影响。结果:生、熟怀地黄对失血性小鼠有明显的作用,给药8天后,特别是熟地黄组恢复较快,已基本恢复,RBC和Hb计数与对照组比较P值分别为0.001和0.01。生、熟地黄对造血干细胞亦有一定的增殖、分化作用,似可说明地黄补血作用与造血干细胞促进血细胞的产生有关。对小鼠骨髓红系造血组细胞的生成:生理盐水组红系集落(个数)为52.4±18.41,生地和熟地组分别为60.2±19.44与125±20.45(P<0.05)。提示地黄补血作用与骨髓造血系统亦有密切相关的作用。⑷地黄炒炭后对止血作用的影响:对生地黄、生地炭、熟地黄、熟地炭,分别制成每100ml煎液含生药100g或含炭药33g制剂。各样品按0.8ml/20g剂量灌胃给于小鼠,从左眼内眦、球后静脉丛取血,统计凝血时间并与生理盐水组进行比较。结果均无显著性差异(P>0.05),提示地黄用于止血似不需要炮制。
当归方面,祖国医学认为,当归味甘而重,故专能补血,其气轻而辛,故又能行血,补中有动,行中有补,为血中之要药。因而,它既能补血,又能活血,既可通经,又能活络。凡妇女月经不调,痛经,血虚闭经,面色萎黄,衰弱贫血,子宫出血,产后瘀血,例经(月经来潮时,出现口鼻流血)等妇女的常见病,都可以用当归治疗。当归是中医中的最常用药多用于煲汤,特别对贫血患者是最好的。还能显著促进机体造血功能,升高红细胞、白细胞和血红蛋白含量。补血养血方面,当归味甘而重,故专能补血,为补血第一药,适用于心肝血虚证所致的面色苍白或萎黄、倦怠乏力、唇甲浅淡无华、头晕目眩、心悸失眠等症。当归与熟地、白芍、川芎配伍,组成补血代表方——“四物汤”,有调经补血之功,尤其适于产后血虚的调治。润肠通便方面,中医认为精血同源,血虚者津液也不足,肠液亏乏易致大便秘结。当归可润肠通便,常与麻仁、苦杏仁、大黄合用治疗血虚便秘;与防风、川芎、芍药、大黄、薄荷叶、麻黄等组成防风通圣散,可泻热通便。调经活血方面,当归气轻而辛,故又能行血,既可通经调经,又能活络止痛,尤其适合女性使用,特别适合月经不调、痛经、血虚闭经等病证,被古人称为“妇科圣药”。与桃仁、红花、熟地黄、白芍、川芎配伍,组成妇科名方——桃红四物汤,常用于经期提前、痛经。对子宫平滑肌的作用方面,当归挥发油对离体子宫均有抑制作用,使节律性收缩呈弛缓状态,并对抗子宫收缩。抗癌作用方面,当归可广泛用于各种肿瘤,尤其是妇科肿瘤,以气血停滞、瘀血凝聚者最宜。对血虚羸瘦的中晚期癌症或手术、放疗、化疗后正气虚弱之患者,亦可选用当归,以扶正抗癌。抗老防老方面,当归煎剂对小鼠学习记忆具有明显的影响,用ㄚ迷宫法测定,当归能改善三氯化铝所致的痴呆,降低痴呆小鼠脑的过氧化酯质水准,和B型单胺氧化的活性,能治疗老年痴呆症。防治冻疮方面,中医认为冻疮虽然病在皮肤上,其实多为素体阳气不足,外寒侵袭,阳气不伸,寒凝血淤而致。因此治疗上常采用温经散寒、活血化淤、消肿止痛。当归生姜羊肉汤出自《伤寒杂病论》。方中当归养血活血,生姜温阳散寒,羊肉补虚生血,全方共济养血活血、温阳散寒之效。免疫作用方面,当归及其萃取物阿魏酸钠和当归多醣对单核-巨噬细胞系统有明显的刺激作用,对免疫功能低下的机体也有免疫调解和恢复作用。当归对健康人的淋巴细胞转化也有促进作用。当归好处多,但当归的禁忌也较多,服用要留意。可以吃当归的人群很多,但是一定要适量服用,要不,很容易产生副作用。过量口服当归煎剂、散剂偶有疲倦、嗜睡等反应,停药后可消失。当归挥发油穴位注射可使病人出现发热、头痛、口干、恶心等反应,可自行缓解。大剂量给药,会导致血压下降,剂量再加大则血压骤降,呼吸停止。当归乙醚提出物毒性较强,少量即可造成死亡。临床使用当归不可过量,服药后也应注意有无不良反应。因而,最好按医嘱服用。
当归有多方面的药理作用。(1)抗血栓形成作用,当归水剂静脉注射或口服对大鼠动脉和静脉旁路血栓的形成有明显抑制作用。(2)改善血液循环作用,当归中的丁基苯酞可增加中脑动脉闭塞(MCAO)术后的软脑膜微动脉管径和血流速度,从而改善软脑膜微循环。脑缺血过程存在神经元凋亡,丁基苯酞还能使低糖低氧诱导的神经细胞凋亡过程减弱或停止,阻止脑梗死面积扩大。(3)对心血管系统的作用,当归煎剂或流浸膏对离体蟾蜍心脏有抑制作用,剂量大时可使心跳停止于舒张期。当归对大鼠心肌缺血再灌注的心律失常具有保护作用,当归注射液0.6g/kg用于大鼠腹腔注射,能使早搏发生率和心律失常总发生率明显减少。(4)改善冠脉循环的作用,静脉注射当归煎剂(2g/kg)可显著增加冠脉流量,降低冠脉阻力和心肌耗氧量,增加心排出量和心搏指数,减轻阻断冠脉时的心肌梗死范围。(5)对平滑的肌的作用,当归有扩张血管作用及对去甲肾上腺素(NA)所致血管痉挛有温和解痉作用。当归挥发油是当归对血管平滑肌起解痉作用的主要活性部分,其中藁本内酯活性最强。当归挥发油对肠平滑肌痉挛也有较强的抑制作用。(6)抗炎和镇痛作用,当归对多种致炎剂引起的急性毛细血管通透性增高、组织水肿及慢性损伤均有显著抑制作用,且能抑制炎症后期肉芽组织增生,但不影响肾上腺及胸腺的重量,提示其抗炎作用不依赖于垂体—肾上腺系统。当归水提取物对腹腔注射醋酸引起的扭体反应表现出镇痛作用,其镇痛作用强度为乙酰水杨酸钠的1.7倍。(7)降血糖作用,实验表明,当归粉(1.5g/kg)口服,对大鼠及家兔实验性高血糖有降血糖作用,其降血糖作用是通过促进胰岛素的分泌来实现的。(8)对肺部的保护作用,当归可扩张大鼠肺动脉,降低急性缺氧性肺动脉高压。当归对慢性阻塞性肺病的肺动脉高压也有一定的降压作用。(9)保肝利胆作用,当归可使胆汁中固体物质重量及胆酸排出量增加,当归能保护细胞ATP酶、葡萄糖-6-磷酸酶、5-核苷酸酶的活性,提示其对保护肝细胞和恢复肝脏某些功能有一定的作用。(10)对肾脏的保护作用,当归对肾脏有一定的保护作用,能改善家兔肾缺血后肾小球滤过功能及肾小管重吸收功能,减轻肾损害,促进肾小管病变的恢复。(11)补血作用,当归多糖可通过直接和(或)间接途径激活造血微环境中的巨噬细胞、淋巴细胞等,也可刺激肌组织,促进其产生造血调控因子,进而促进功能造血干细胞粒细胞巨噬细胞集落成单位(CFU-GM)的增殖分化,刺激骨髓粒单系造血。此外,当归还呈现如下作用:对子宫平滑肌的作用、对心血管系统的作用、对血液系统的作用、抗炎作用、神经系统抑制作用、抗菌作用、平喘作用。另外,临床应用方面,当归能够治疗肌肉、关节疼痛及神经痛,治疗慢性气管炎,治疗慢性盆腔炎,治疗月经病,治疗高血压病,治疗带状疱疹,治疗鼻炎。
党参(学名;Codonopsis pilosula(Franch.)Nannf.)桔梗科党参属,多年生草本植物。党参的主要功效是补气。最宜用于平素倦怠乏力、精神不振。语音低沉、自觉气短、稍一活动就喘促的肺气虚弱者。侧重于脾胃气虚的人,四肢无力,食欲不振,大便稀溏,也宜使用党参。常用党参与白术、茯苓、炙甘草配伍,这就是补气健脾的着名方剂四君子汤。肺气与脾气都虚的,又宜用党参与黄芪、白术、茯苓、陈皮、当归、升麻、柴胡、炙甘草、生姜、大枣配伍,这就是有名的补中益气汤。
党参补气兼能养血,这是它的一大特点。所以气血两虚,气短心悸,疲倦乏力,面色苍白,头昏眼花,胃口不好,大便稀软,容易感冒的人,也宜服用党参。实验证明,党参能使红细胞增多、血红蛋白增加,所以贫血病人食用党参很有益处。因化疗和放射疗法引起的白细胞下降,服用党参也有促使白细胞回升的效果。近年还发现,党参与黄芪、白术配合可使慢性肾炎病人的尿蛋白减少。
党参的作用包括多方面。具体的说,(1)对血细胞的影响:党参根的醇、水浸膏口服或皮下注射,可使正常兔的红细胞及血红蛋白略有增加;摘除脾脏后,作用显著减弱,故推测其补血作用,可能与脾脏有关,此时白细胞则有减少倾向。党参浸液1:40在试管内无溶血现象,但与红细胞作用后,可变色,发生浑浊、沉淀。(2)对血糖的影响:对兔腹部皮下注射党参浸膏,可使血糖升高;但如注射发酵后的浸膏或灌胃给药,则无比作用,故认为其升高血糖乃因根中含多量糖分所致;它也不能抑制因注射利尿素而发生的神经性高血糖。据初步试验,北党参灌胃,能升高血糖。(3)降压作用:醇、水浸膏静脉或腹腔注射,能降低麻醉犬的血压,据初步分析,认为是属于末梢性的;并有某些抗肾上腺素作用;其水浸液或醇、水浸出液也有降低麻醉动物血压的作用,并能抑制离体蟾蜍心脏。对慢性高血压犬,每日灌服水浸液4克(生药)/公斤,未见有降压作用。同属植物的根的提取物或总甙,长期(40天)喂兔,可增加红细胞敷(17.5%),增加体重(23%);对松节油引起的白细胞增多症有预防及治疗功效;长期口服,内脏器官未发现有何病理改变。(4)对中枢的作用:党参煎剂可对抗硝酸士的宁引起的小鼠惊厥,延长惊厥出现的时间,延长小鼠的存活时间,也有对抗电惊厥作用。党参煎剂能显着对抗东莨菪碱所致的小鼠记忆获得障碍;对乙醇所致小鼠记忆再现障碍也有对抗作用。(5)对心血管的作用:醇浸液及水浸液均有降压作用,其降压作用是由於外周血管扩张所致,乙醇浸液对离体蟾蜍心脏有抑制作用。(6)对血液的作用:党参水溶物灌胃,对ADP诱导的大鼠血小板聚集有抑制作用。商品党参可使兔的红细胞显着增加,而白细胞明显降低。(7)抗溃疡作用:党参具有对抗胃粘膜损伤及增强胃粘膜细胞保护作用。(8)对免疫功能的影响:党参煎剂可明显促进ConA活化的脾淋巴细胞DNA和蛋白质的生物合成,对白细胞介质-2(IL-2)的产生也有明显增强作用。对小鼠网状内皮系统的吞噬功能也有增强作用。(9)耐疲劳及抗缺氧作用:党参水煎剂可延长小鼠负重游泳时间;并可显着延长缺氧小鼠的存活时间。
阿胶具有补血、止血、滋阴、润燥之功效。主血虚证、虚劳咯血、吐血、尿血、便血、血痢、妊娠下血、崩漏、阴虚心烦失眠、肺虚澡咳、虚风内动之痉厥抽搐。阿胶的作用有诸多方面。例如,(1)对造血系统的作用:阿胶有强大的补血作用,疗效优于铁剂。(2)抗休克作用:能使极低水平之血压恢复至正常高度,且作用较为持久。(3)对进行性营养性肌变性症的影响:豚鼠试验中可发生类似人的营养性进行性肌变性症。(4)对钙代谢的影响:有正钙平衡作用,这对肌变性症患者亦有利。中医临床上主要用阿胶治疗因血虚引起的病症。随着人们生活质量的提高,民间越来越多的人用阿胶强身健体,美容养颜。(1)治疗血液病:治疗缺铁性贫血,再生障碍性贫血,血小板减少,白细胞减少等症效果明显,治疗贫血含有阿胶的中成药有:阿胶补血口服液、山东阿胶膏、复方阿胶浆、当归养血丸等。(2)保胎安胎:阿胶还用于妊娠期胎动不安,先兆流产,习惯性流产。(3)月经病:阿胶以滋阴补血为主,兼祛瘀血,并有一定的止血效果。对于月经病,血虚者可用阿胶补益,血多者用来固摄,血少者用来行血。(4)出血病:经配伍,阿胶可用于多种出血症的治疗,如吐血、便血、血尿、月经过多、崩漏及产后下血等。(5)防治老年病和延缓衰老:临床上充分发挥阿胶的养血、补血、益气的作用,用来调治多种老年性疾病,如更年期综合征、失眠、病态窦房结综合征、低血压、糖尿病、风湿性关节炎、骨质疏松、老年痴呆等。(6)防癌抗癌:表现在提高肿瘤患者淋巴细胞转化率,抑制肿瘤生长,改减其他抗癌药物和化疗的毒性,使之有可能顺利完成治疗过程。中医临床上常用阿胶配以其他药物治疗白血病、鼻咽癌、食道癌、肺癌、乳腺癌等。(7)增强体质和美容:阿胶不温不燥,老少皆宜,一年四季均可用,是强身健体的滋补佳品。至今在上海、江苏、浙江的许多家庭冬季用阿胶再配以冰糖、核桃仁、黑芝麻、桂元、大枣等做成稠膏,早晚温开水冲服,用后感到身上有气力、抗寒力增强、感冒少。孕妇产前产后服用阿胶有利于小儿的成长和产后身体的恢复。阿胶富含蛋白质降解成分,通过补血起到滋润皮肤的作用,有利于皮肤的保健,使用后会使面色红润,肌肤细嫩,有光泽,弹性好,而且有一定的祛癍效果,所以也用以护肤养颜。阿胶大量应用于中医配方和民间,也大量用于中成药生产。2000年国家批准的中成药中有181种含有阿胶。
葡萄糖酸亚铁,分子式为C12H22O14Fe·2H2O,相对分子质量为482.18。在食品中可用作护色剂、营养强化剂,可由还原铁中和葡萄糖酸而成。葡萄糖酸亚铁的特点是生物利用率高,在水中溶解性好,风味平和无涩味,在乳饮料中强化较多。葡萄糖酸亚铁作为一种优良的补铁剂,亚铁吸收率高,其进入血液后,立刻氧化为三价铁离子,并与血浆中转铁蛋白结合,成血浆铁,并以转铁蛋白为载体转运到肝,脾,骨等组织,以铁蛋白形式贮存,在骨中铁蛋白的铁可结合成血红蛋白,在骨骼肌中成为肌红蛋白,在缺铁时,血浆铁转运率增加,吸收率也加速,使铁吸收量增加。葡萄糖酸亚铁主要经肠道,皮肤排泄,少量经胆汁和汗中排泄。葡萄糖酸亚铁与硫酸亚铁相同,参与血红蛋白的合成,在传递氧和人体代谢活动中起重要作用。葡萄糖酸亚铁适应症状主要是用于因慢性失血,月经过多,孕妇,哺乳期妇女,儿童发育期所致的缺铁性贫血。
本发明产品配方是以两类成分综合利用,以求效果更佳;本产品为口服液制剂,具有吸收快、奏效迅速、使用方便、质量稳定、易携带、易保存和服用量更准确等优点,必将越来越受到人们的青睐。因此,对海瑞康牌血尔红口服液进行研发用以满足市场需求,必将具有广阔的市场前景和深远的社会效益。
贫血是由全身细胞总量或血红蛋白总量减低,致使血液携氧功能不足为共同表现的一类血液疾病,祖国医药认为:血的生成与脾的关系至为密切,故《内经》有“中焦受气取汁变化而赤是谓血”;《灵枢》“脾胃不足,皆为血病”;《脾肋论》的论述,若脾胃虚损,功能失调,则水谷收纳不足,精微物质乏源或者精微物质吸收利用障碍,则影响血液的生成。营养性贫血由于营养不良,造血障碍引起,缺铁性贫血属于营养性贫血之列。临床西医多采用积极治疗原发疾病,制止过多失血,杀虫及补充铁剂等方法来治疗本病;中医则以益气生血为基本原则综合症状“辨证加减”,施以补益肝肾、温补脾肾、健脾益气、益气养阴等法。本配方是以祖国医药学理论为依据,参考古今改善贫血的验方,结合现代医药研究的最新进展,按照中医理论组放原则而成。海瑞康牌雪尔红口服液是根据这样的作用机制,其目的是补充人体因缺乏生血所必需的营养物质,预防使血红蛋白形成或红细胞生成不足,导致造血功能低下。本配方中为黄芪,大补脾腑之气,以资气血生化之源;当归,甘辛而温,养血和营,阳生阴长,气旺血生;阿胶,熟地黄滋阴养血,党参补气养血;防止缺铁性贫血的葡萄糖酸亚铁。
在本发明组合物的配方中,黄芪具有改善心脑血管的功能,减轻由缺血引起的心肌细胞、心肌组织和红细胞内钙积累,并能保护红细胞钙泵功能,从而减轻缺血缺氧造成的心肌超微结构改变。当归能增加外周红细胞、白细胞、血红蛋白及骨髓有核细胞数。熟地黄可增强免疫功能,有延缓衰老、抗肿瘤、镇静、抗辐射、抗氧化等作用,对蛋白质代谢,糖皮质激素,血糖等均有影响。党参有抗氧化,促进酰胆碱的数量增加,改善记忆,促进红细胞生成,扩张微血管,增加血流量的作用。阿胶对骨髓造血功能有一定作用,能迅速恢复失血性贫血之血红蛋白和红细胞,具有强大的补血作用。葡萄糖酸亚铁具有合成血红蛋白,合成肌红蛋白,合成贮存铁等;是构成各种金属酶的必需成份或活化某些金属酶和它的辅助因子。
贫血对健康最根本的危害之一就是携氧能力低下,影响全身各个系统功能的发挥,导致一系列常见症状和体征影响人们的生命、生存质量。本发明组合物以阿胶、熟地黄入药,甘温味厚,而质柔润,长于滋阴养血,当归,补血养肝,和血调经,血为有形之物,气属无形之用,血之运行有赖于气,故用党参、黄芪之大补脾肺之气,以资气血生化之源。葡萄糖酸亚铁为补铁。适用于营养性贫血者。由于其配方独特,产品安全无毒,保健功能明确,其发展前景广阔。本发明组合物其原料易得、工艺合理、生产成本低、剂型合理、携带方便,适合中低收入者。因此,可以预见此产品上市具有广泛的发展前景,必将产生巨大的社会效益和很好的经济效益。
本发明中药组合物的方中黄芪,大补脾肺之气,以资气血生化之源;当归,甘辛而温,养血和营,阳生阴长,气旺血生;阿胶,熟地黄滋阴养血,党参补气益血;葡萄糖酸亚铁补铁。功效:补气养血,滋阴养血。保健功能:改善营养性贫血。黄芪为豆科植物蒙古黄芪或膜荚黄芪的干燥根。黄芪内含有黄芪甙、黄芪多糖、胆碱、蔗糖、黄酮、多种氨基酸、苦味素、叶酸、黄烷化合物及含有硒、硅、锌、钴等多种微量元素、胡萝卜甙、大豆皂甙等。性味:甘、微温;归脾、肺经;功能:补气升阳,益卫固表,托毒生肌,利水退肿。主治与应用:黄芪为补气要药,生黄芪走表,偏于固表止汗,托毒排脓;炙则走里,重在补气升阳,利水消肿。当归为伞形科多年生草本植物当归的根。当归入药由来已久,早在《神农本草经》就将它列于可攻可补的中品药,既可扶正补养,又可攻邪治病,当归的首要功效是补血。当归内含有阿魏酸、多种氨基酸、当归多糖、嘧啶、嘌呤、维生素B12、维生素E、亚油酸、丁二酸、烟酸等,并含锰、锌等微量元素,含有挥发油。性味:甘、辛、温;归心、肝、脾经;功能:补血活血,调经止痛、润肠通便。主治与应用:①治血虚症,常配伍黄芪同用,治血虚证有效。②治月经不调、闭经、痛经,为妇科调经要药。熟地黄为玄参科多年生草本植物地黄的根。熟地黄内含有谷甾醇、甘露醇、少量豆甾醇、地黄素、梓醇、二氢梓醇、已酰梓醇、胡萝卜甙、地黄甙、单萜和甙类,也含有机酸、葡萄糖、蔗糖、果糖、棉籽糖、甘露三醇、半乳糖、维生素A、多种氨基酸、多种微量元素。性味:甘、微温;归经:入肝、肾经;功效:养血滋阴,补精益髓。主治与应用:①治血虚萎黄、眩晕、心悸、失眠、月经不调,崩漏等症。②治肾阴不足,潮热,盗汗、遗精、消渴等症。③凡腰酸脚软、头晕眼花、耳鸣耳聋,须发早白等一切精血亏虚之症均可应用。党参为桔梗科党参植物的干燥根。党参内含有豆甾醇、皂甙、菊糖、胆碱、党参酸、丁香甙、烟碱、氨基酸、微量元素、及维生素B1、B2、挥发油等。性味:甘,平;归经:入脾、肺经;功效:补中益气,生津和胃。主治与应用:用于治疗气虚症,症见于气短心悸,体倦无力,少食便溏,面目浮肿,久泻脱肛,津亏舌干口渴症。①贫血:配伍党参、黄芪、阿胶、鹿角胶、龙眼肉、白术、当归、大枣等。②因化疗或放疗引起的白细胞减少症:配伍党参、黄芪、鸡血藤、女贞子、淫羊藿、白术、山药、鹿角胶等。阿胶为马科动物驴的皮,经漂泡去毛熬制而成的胶块。阿胶含有明胶、骨胶,含氮16.43%~16.54%,多种蛋白质、氨基酸、钙和硫等,其中赖氨酸、精氨酸、组氨酸等。性味:甘、平;归经:入肺、肝、肾经;功能:补血止血,滋阴润肺。主治与应用:①补血之要药,治血虚眩晕,心悸等症,多与党参、黄芪、当归、熟地等益气补血药同用。②止血要药,用于吐血、衄血、便血、崩漏,单用或配伍莆黄、生地、艾叶炭等皆有效。③补血滋阴,治阴虚心烦、失眠等症。葡萄糖酸亚铁是属营养素强化剂,含铁量为11%。体内的铁按其功能可分为必需与非必需两部分。必需部分占体内铁总量的70%,存在于血红蛋白、肌红蛋白、血红素酶类、辅助因子和运输铁中;非必需部分则作为体内储备铁,主要以铁蛋白和含铁血黄素的形式存在于肝、脾和骨髓中。铁是人体中含量最丰富的一种必需元素,能合成血红蛋白,并且是构成各种金属酶的所需的必需成份,能供活化某些金属酶和它的辅助因子参与激素的合成或增强激素的作用,有维护机体正常的免疫功能,增强中性粒细胞杀菌及吞噬的功能。缺铁性贫血是全球性疾病,世界卫生组织调查结果发病率成年男性10%,女性40%,儿童50%;我国报道妇女和儿童发病率最高。由于参与人体代谢的很多酶含有铁,故人体缺铁时很多酶活性降低,导致多种代谢紊乱,从而影响多个器官的功能。铁是人体中最丰富的微量元素,很多含铁酶控制着机体重要的氧化、水解和转化过程,因此与组织吸收、氧化磷酸化、卟啉代谢、胶原合成、淋巴细胞与粒细胞功能、神经介质的合成与分解、躯体与神经组织的发育有关。缺铁性贫血时,血红蛋白、肌红蛋白、铁蛋白、含铁血黄素等降低的同时,很多含铁酶或铁依赖酶活性降低,影响电子传递系统,可引起脂质、蛋白质及糖代谢异常,严重影响机体代谢的正常进行,缺铁可引起多种组织改变和功能换调,骨髓有核细胞DNA和RNA含量减少。贫血是由全身细胞总量或血红蛋白总量减低,致使血液携氧功能不足为共同表现的一类血液疾病,祖国医药认为:血的生成与脾的关系至为密切,故《内经》有“中焦受气取汁变化而赤是谓血”;《灵枢》“脾胃不足,皆为血病”;《脾肋论》的论述,若脾胃虚损,功能失调,则水谷收纳不足,精微物质乏源或者精微物质吸收利用障碍,则影响血液的生成。营养性贫血由于营养不良,造血障碍引起,缺铁性贫血属于营养性贫血之列。临床西医多采用积极治疗原发疾病,制止过多失血,杀虫及补充铁剂等方法来治疗本病;中医则以益气生血为基本原则综合症状“辨证加减”,施以补益肝肾、温补脾肾、健脾益气、益气养阴等法。本配方是以祖国医药学理论为依据,参考古今改善贫血的验方,结合现代医药研究的最新进展,按照中医理论组放原则而成。海瑞康牌雪尔红口服液是根据这样的作用机制,其目的是补充人体因缺乏生血所必需的营养物质,预防使血红蛋白形成或红细胞生成不足,导致造血功能低下。本配方中为黄芪,大补脾腑之气,以资气血生化之源;当归,甘辛而温,养血和营,阳生阴长,气旺血生;阿胶,熟地黄滋阴养血,党参补气养血;防止缺铁性贫血的葡萄糖酸亚铁。
就本发明黄芪当归阿胶口服液的技术效果而言,本发明进行的一些试验,例如高温处置试验可以得到证实。本发明实施例1所得黄芪当归阿胶口服液改善人体气血功能和提高免疫力的功能通过大量的人群使用其效果也已经得到证实。另外,本发明黄芪当归阿胶口服液还呈现其它一些技术效果,例如,本发明进行如下高温处置试验:将实施例1~10所得口服液,置于40℃温度处放置6个月(可称为高温6月处置),在6个月时观察是否有沉淀物生成,以及照试验例1所述四类测定目标物含量相对于其0月时的变化。结果显示,6月时,在口服液的性状方面,实施例1~实施例9全部口服液存在不同程度的沉淀物,振摇后呈悬浮状态;而实施例10全部九种口服液均不存在沉淀物,仍然保持澄清溶液状态。在口服液的化学成分变化方面,除毛蕊异黄酮葡萄糖苷外,不同口服液的其余各测定目标物的含量均相对于该样品0月时无明显变化;但是不同口服液样品在毛蕊异黄酮葡萄糖苷方面在6月时呈现不同的变化,以6月相对百分含量(相对于0月时的相对百分含量,即6月浓度除以0月浓度再乘以100%所得百分数)表征,实施例1~实施例9全部口服液均在84~88%范围,而实施例10全部口服液均在98.2~99.8%范围,显著高于实施例1~实施例9,例如实施例1为86.3%,实施例101为98.7%。在补充的试验即实施例11中,分别参照实施例10,不同的仅是仅在相应步骤添加枸橼酸钠而不加山梨醇,所得口服液经同样的高温6月处置后结果全部口服液均存在不同程度的沉淀物,振摇后呈悬浮状态,且毛蕊异黄酮葡萄糖苷6月相对百分含量均在85~87范围。在补充的试验即实施例12中,分别参照实施例10,不同的仅是仅在相应步骤添加山梨醇而不加枸橼酸钠,所得口服液经同样的高温6月处置后结果全部口服液均存在不同程度的沉淀物,振摇后呈悬浮状态,且毛蕊异黄酮葡萄糖苷6月相对百分含量均在86~89%范围。在补充的试验即实施例13中,分别参照实施例10,不同的仅是将枸橼酸钠和山梨醇提前到步骤(1)首次煎煮前添加,所得口服液经同样的高温6月处置后结果全部口服液均存在不同程度的沉淀物,振摇后呈悬浮状态,且毛蕊异黄酮葡萄糖苷6月相对百分含量均在87~90%范围。实施例11~实施例13各口服液的其余各种测定目标物在经高温6月处置前后无明显差异。此外,本发明实施例1和实施例101所得两种典型的口服液在临床上用于改善人体气血功能和提高免疫力的功能方面呈现基本上相同的疗效,并且在改善人体气血功能和提高免疫力方面均具有显著治疗效果。例如使用实施例1和实施例101两种口服液分别用于120名和90名贫血受试者,均得到完全治愈。
本发明将黄芪、当归、熟地黄、党参、阿胶、葡萄糖酸亚铁组合,制成的口服溶液不但能有效的改善人体气血功能,还能提高免疫力。
具体实施方式
通过下面的实施例可以对本发明进行进一步的描述,然而,本发明的范围并不限于下述实施例。本领域的专业人员能够理解,在不背离本发明的精神和范围的前提下,可以对本发明进行各种变化和修饰。本发明对试验中所使用到的材料以及试验方法进行一般性和/或具体的描述。虽然为实现本发明目的所使用的许多材料和操作方法是本领域公知的,但是本发明仍然在此作尽可能详细描述。
在以下各实例中,制备组合物时,如未特别说明每次投料以黄芪计不少于1200g,所制得的口服液在最后用玻璃瓶分装,每瓶10ml;但是在下文描述配方时,均以每制备100ml口服液量的中药组合物投料量表示。
在本发明中,制成的呈品服液形式的中药组合物,可以称之为血尔红口服液;或者由于其中包括黄芪、当归、阿胶三种重要药材,亦可称为海瑞康牌黄芪当归阿胶口服液。
实施例1:黄芪当归阿胶口服液中药组合物的制备
配方:黄芪12g、当归5g、熟地黄4g、党参4g、阿胶2g、葡萄糖酸亚铁0.32g、白砂糖12g、纯化水适量制成100mL。
制法:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次(第一次加6倍量的纯化水煎煮2h,过滤,得滤液;第二次滤渣加6倍量的纯化水煎煮2h,过滤,得滤液),合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比1:1;加入95%的乙醇使含醇量达60%,静置醇沉24小时,取上清液,过滤,得滤液;
(3)将步骤(2)所得滤液在70℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08(测量温度40℃),得中药提取液,备用;
(4)将阿胶捣成小碎块,加10倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和调味剂合并,加3倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌(105℃灭菌45min),制成口服液形式的中药组合物。
实施例2:黄芪当归阿胶口服液中药组合物的制备
配方:黄芪12g、当归4.5g、熟地黄4.5g、党参3.5g、阿胶2.5g、葡萄糖酸亚铁0.25g、白砂糖14g、纯化水适量制成100mL。
制法:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次(第一次加5倍量的纯化水煎煮3h,过滤,得滤液;第二次滤渣加8倍量的纯化水煎煮2h,过滤,得滤液),合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比0.8:1;加入98%的乙醇使含醇量达55%,静置醇沉20小时,取上清液,过滤,得滤液;
(3)将步骤(2)所得滤液在80℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08(测量温度40℃),得中药提取液,备用;
(4)将阿胶捣成小碎块,加8倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和调味剂合并,加4倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌(105℃灭菌45min),制成口服液形式的中药组合物。
实施例3:黄芪当归阿胶口服液中药组合物的制备
配方:黄芪12g、当归5.5g、熟地黄3.5g、党参4.5g、阿胶1.5g、葡萄糖酸亚铁0.35g、白砂糖10g、纯化水适量制成100mL。
制法:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次(第一次加8倍量的纯化水煎煮1h,过滤,得滤液;第二次滤渣加5倍量的纯化水煎煮3h,过滤,得滤液),合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比1.2:1;加入95%的乙醇使含醇量达65%,静置醇沉30小时,取上清液,过滤,得滤液;
(3)将步骤(2)所得滤液在60℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08(测量温度40℃),得中药提取液,备用;
(4)将阿胶捣成小碎块,加12倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和调味剂合并,加2倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌(105℃灭菌45min),制成口服液形式的中药组合物。
实施例4:黄芪当归阿胶口服液中药组合物的制备
配方:黄芪12g、当归6g、熟地黄3g、党参5g、阿胶1g、葡萄糖酸亚铁0.2g、白砂糖16g、纯化水适量制成100mL。
制法:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次(第一次加7倍量的纯化水煎煮2h,过滤,得滤液;第二次滤渣加7倍量的纯化水煎煮1h,过滤,得滤液),合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比0.9:1;加入90%的乙醇使含醇量达65%,静置醇沉25小时,取上清液,过滤,得滤液;
(3)将步骤(2)所得滤液在75℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08(测量温度40℃),得中药提取液,备用;
(4)将阿胶捣成小碎块,加9倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和调味剂合并,加2.5倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌(105℃灭菌45min),制成口服液形式的中药组合物。
实施例5:黄芪当归阿胶口服液中药组合物的制备
配方:黄芪12g、当归4g、熟地黄5g、党参3g、阿胶3g、葡萄糖酸亚铁0.4g、白砂糖8g、纯化水适量制成100mL。
制法:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次(第一次加6倍量的纯化水煎煮2h,过滤,得滤液;第二次滤渣加5倍量的纯化水煎煮2h,过滤,得滤液),合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比1.1:1;加入96%的乙醇使含醇量达62%,静置醇沉28小时,取上清液,过滤,得滤液;
(3)将步骤(2)所得滤液在65℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08(测量温度40℃),得中药提取液,备用;
(4)将阿胶捣成小碎块,加11倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和调味剂合并,加3.5倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌(105℃灭菌45min),制成口服液形式的中药组合物。
实施例6:黄芪当归阿胶口服液中药组合物的制备
配方:黄芪12g、当归5g、熟地黄4g、党参4g、阿胶2g、葡萄糖酸亚铁0.32g、白砂糖12g、纯化水适量制成100mL。
制法:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次(第一次加6.5倍量的纯化水煎煮2.5h,过滤,得滤液;第二次滤渣加7.5倍量的纯化水煎煮1.5,过滤,得滤液),合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比1:1;加入97%的乙醇使含醇量达60%,静置醇沉26小时,取上清液,过滤,得滤液;
(3)将步骤(2)所得滤液在70℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08(测量温度40℃),得中药提取液,备用;
(4)将阿胶捣成小碎块,加11倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和调味剂合并,加4倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌(105℃灭菌45min),制成口服液形式的中药组合物。
实施例7:黄芪当归阿胶口服液中药组合物的制备
配方:黄芪12g、当归5g、熟地黄4g、党参4g、阿胶2g、葡萄糖酸亚铁0.32g、白砂糖12g、纯化水适量制成100mL。
制法:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次(第一次加7倍量的纯化水煎煮1h,过滤,得滤液;第二次滤渣加6.5倍量的纯化水煎煮1.5h,过滤,得滤液),合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比0.9:1;加入98%的乙醇使含醇量达65%,静置醇沉24小时,取上清液,过滤,得滤液;
(3)将步骤(2)所得滤液在75℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08(测量温度40℃),得中药提取液,备用;
(4)将阿胶捣成小碎块,加8倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和调味剂合并,加4倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌(105℃灭菌45min),制成口服液形式的中药组合物。
实施例8:黄芪当归阿胶口服液中药组合物的制备
配方:黄芪12g、当归5g、熟地黄4g、党参4g、阿胶2g、葡萄糖酸亚铁0.32g、白砂糖12g、纯化水适量制成100mL。
制法:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次(第一次加5倍量的纯化水煎煮3h,过滤,得滤液;第二次滤渣加6倍量的纯化水煎煮2h,过滤,得滤液),合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比0.9:1;加入95%的乙醇使含醇量达60%,静置醇沉20~30小时,取上清液,过滤,得滤液;
(3)将步骤(2)所得滤液在76℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08(测量温度40℃),得中药提取液,备用;
(4)将阿胶捣成小碎块,加11倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和调味剂合并,加3倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌(105℃灭菌45min),制成口服液形式的中药组合物。
实施例9:黄芪当归阿胶口服液中药组合物的制备
配方:黄芪12g、当归5g、熟地黄4g、党参4g、阿胶2g、葡萄糖酸亚铁0.32g、白砂糖12g、纯化水适量制成100mL。
制法:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次(第一次加7倍量的纯化水煎煮2h,过滤,得滤液;第二次滤渣加8倍量的纯化水煎煮1.5h,过滤,得滤液),合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比1:1;加入95%的乙醇使含醇量达60%,静置醇沉20小时,取上清液,过滤,得滤液;
(3)将步骤(2)所得滤液在68℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08(测量温度40℃),得中药提取液,备用;
(4)将阿胶捣成小碎块,加9倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和调味剂合并,加2倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌(105℃灭菌45min),制成口服液形式的中药组合物。
实施例10:黄芪当归阿胶口服液中药组合物的制备
分别参照实施例1~实施例9的配方和制法,不同的仅是,还向步骤(2)所得滤液中添加枸橼酸钠(药材黄芪和枸橼酸钠的重量比为12:0.1)和山梨醇(药材黄芪和山梨醇的重量比为12:0.5),再接着进行步骤(4)的减压回收乙醇和浓缩操作,得到10批口服液,分别依次可称为实施例101、实施例102……实施例109的样品。
试验例1:以上各实施例1~10所得口服液,分别照《中国药典》2015年版一部相应药材品种的方法测定其中的典型成分含量,测定目标物包括:黄芪(测定黄芪甲苷、毛蕊异黄酮葡萄糖苷)、熟地黄(测定毛蕊花糖苷)、当归(测定阿魏酸)、党参(用RP-HPLC法测定党参炔苷,测定方法:王润生等,山西党参药材中党参炔苷的含量分析,药物分析杂志,2007年08期)。结果显示,实施例10所得9批口服液分别与其相应的实施例1~实施例9批口服液相同,未见差异,例如实施例1口服液与实施例101口服液在上述四类测定目标物含量方面无差异。另外,以上各实施例1~10所得口服液在制备后均呈澄清溶液,未见沉淀物。
Claims (12)
1.一种中药组合物,其由黄芪1200重量份、当归400~600重量份、熟地黄300~500重量份、党参300~500重量份、阿胶100~300重量份、葡萄糖酸亚铁20~40重量份以及药用辅料制成口服液形式的液体药剂;该中药组合物由包括如下步骤的方法制得:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次,合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比0.8~1.2:1;加入乙醇使含醇量达55~65%,静置醇沉20~30小时,取上清液,过滤,得滤液,向其中添加枸橼酸钠和山梨醇,药材黄芪和枸橼酸钠的重量比为12:0.1,药材黄芪和山梨醇的重量比为12:0.5;
(3)将步骤(2)所得滤液在60~80℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08,测量温度40℃,得中药提取液,备用;
(4)将阿胶捣成小碎块,加8~12倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和任选的调味剂合并,加2~4倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌,即得。
2.根据权利要求1的中药组合物,其由黄芪1200重量份、当归450~550重量份、熟地黄350~450重量份、党参350~450重量份、阿胶150~250重量份、葡萄糖酸亚铁25~35重量份以及药用辅料制成。
3.根据权利要求1的中药组合物,其由黄芪1200重量份、当归500重量份、熟地黄400重量份、党参400重量份、阿胶200重量份、葡萄糖酸亚铁32重量份以及药用辅料制成。
4.根据权利要求1的中药组合物,其制备每100ml使用的黄芪药材量为8~16g。
5.根据权利要求1的中药组合物,其制备每100ml使用的黄芪药材量为10~14g。
6.根据权利要求1的中药组合物,其制备每100ml使用的黄芪药材量为12g。
7.根据权利要求1的中药组合物,其中所述调味剂选自阿司巴坦、安赛蜜、糖精钠、蔗糖。
8.根据权利要求1的中药组合物,其中步骤(1)中,取黄芪、当归、熟地黄、党参,加纯化水煎煮二次,第一次加5~8倍量的纯化水煎煮1~3h,过滤,得滤液;第二次滤渣加5~8倍量的纯化水煎煮1~3h,过滤,得滤液,合并两次滤液。
9.根据权利要求1的中药组合物,其中步骤(2)中,所用乙醇是浓度大于等于90%的乙醇。
10.根据权利要求1的中药组合物,其中步骤(6)中,所述热压灭菌是105℃灭菌45min。
11.制备权利要求1-10任一项所述中药组合物的方法,包括如下步骤:
(1)取黄芪、当归、熟地黄、党参,加纯化水煎煮二次,合并两次滤液;
(2)将合并的滤液,减压浓缩至药液与药材重量比0.8~1.2:1;加入乙醇使含醇量达55~65%,静置醇沉20~30小时,取上清液,过滤,得滤液,向其中添加枸橼酸钠和山梨醇,药材黄芪和枸橼酸钠的重量比为12:0.1,药材黄芪和山梨醇的重量比为12:0.5;
(3)将步骤(2)所得滤液在60~80℃温度下减压回收乙醇,至无醇味,无醇液减压浓缩至相对密度为1.05~1.08,测量温度40℃,得中药提取液,备用;
(4)将阿胶捣成小碎块,加8~12倍量的纯化水加热使其完全溶解,过滤,备用;
(5)将葡萄糖酸亚铁和任选的调味剂合并,加2~4倍量的纯化水加热溶解,备用;
(6)将以上步骤(3)、(4)、(5)各药液合并,混合均匀,加纯化水定容,搅拌均匀,过滤,分装、封口,热压灭菌,即得。
12.权利要求1-10任一项所述中药组合物或者权利要求11所述方法制得的中药组合物在制备用于改善人体气血功能和提高免疫力的产品中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711186119.2A CN107929420B (zh) | 2017-11-23 | 2017-11-23 | 改善人体气血功能和提高免疫力的中药组合物和检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711186119.2A CN107929420B (zh) | 2017-11-23 | 2017-11-23 | 改善人体气血功能和提高免疫力的中药组合物和检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107929420A CN107929420A (zh) | 2018-04-20 |
CN107929420B true CN107929420B (zh) | 2021-01-19 |
Family
ID=61930206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711186119.2A Active CN107929420B (zh) | 2017-11-23 | 2017-11-23 | 改善人体气血功能和提高免疫力的中药组合物和检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107929420B (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109771510A (zh) * | 2019-03-20 | 2019-05-21 | 江西天元药业有限公司 | 调节人体精气神和阴阳平衡的中药组合物和制备工艺 |
CN109731045A (zh) * | 2019-03-20 | 2019-05-10 | 江西天元药业有限公司 | 用于抑制肿瘤细胞生长预防治疗癌症的中药组合物 |
CN109718302A (zh) * | 2019-03-20 | 2019-05-07 | 江西天元药业有限公司 | 治疗调节和延迟女性更年期综合征的中药组合物 |
CN109731046A (zh) * | 2019-03-20 | 2019-05-10 | 江西天元药业有限公司 | 改善人体肾功能增强人体肾气的中药组合物的中药组合物 |
CN109718303A (zh) * | 2019-03-20 | 2019-05-07 | 江西天元药业有限公司 | 提高女性卵巢功能养颜美容改善女性皮肤的中药组合物 |
CN109718305A (zh) * | 2019-03-20 | 2019-05-07 | 江西天元药业有限公司 | 改善人体气血功能提高耐缺氧延缓衰老的中药组合物 |
CN109718304A (zh) * | 2019-03-20 | 2019-05-07 | 江西天元药业有限公司 | 改善人体心脑血管功能微循环及预防血栓的中药组合物 |
CN109799303B (zh) * | 2019-03-21 | 2021-07-27 | 湖南安邦制药有限公司 | 止血调经组合物的指纹图谱构建方法、定量检测方法及质量检测方法 |
CN109828066B (zh) * | 2019-03-29 | 2021-11-05 | 齐齐哈尔大学 | 液相色谱质谱联用法测定中药中化学成分的方法及应用 |
CN109900847B (zh) * | 2019-03-29 | 2021-03-23 | 齐齐哈尔大学 | 一种治疗胃溃疡的中药复方附子理中汤的质量评价方法 |
CN112834650B (zh) * | 2021-01-12 | 2022-10-21 | 湖南天劲制药有限责任公司 | 一种强骨生血口服液的质量检测方法 |
CN114272354B (zh) * | 2022-02-21 | 2023-04-28 | 澳门大学 | 用于预防和改善老年痴呆的中药组合物、其制备方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1650922A (zh) * | 2004-02-06 | 2005-08-10 | 李湛明 | 治疗血亏气虚、月经不调的中药组合物及其制备方法 |
CN102145055A (zh) * | 2011-03-30 | 2011-08-10 | 呼伦贝尔松鹿制药有限公司 | 一种无糖型消栓口服液及其制备方法 |
CN103134867A (zh) * | 2012-12-11 | 2013-06-05 | 河南省康星药业股份有限公司 | 稳定的黄芪超微粉中毛蕊异黄酮葡萄糖苷含量测定方法 |
CN104713956A (zh) * | 2014-12-30 | 2015-06-17 | 上海现代中医药股份有限公司 | 一种黄芪川芎提取物指纹图谱的测定方法 |
-
2017
- 2017-11-23 CN CN201711186119.2A patent/CN107929420B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1650922A (zh) * | 2004-02-06 | 2005-08-10 | 李湛明 | 治疗血亏气虚、月经不调的中药组合物及其制备方法 |
CN102145055A (zh) * | 2011-03-30 | 2011-08-10 | 呼伦贝尔松鹿制药有限公司 | 一种无糖型消栓口服液及其制备方法 |
CN103134867A (zh) * | 2012-12-11 | 2013-06-05 | 河南省康星药业股份有限公司 | 稳定的黄芪超微粉中毛蕊异黄酮葡萄糖苷含量测定方法 |
CN104713956A (zh) * | 2014-12-30 | 2015-06-17 | 上海现代中医药股份有限公司 | 一种黄芪川芎提取物指纹图谱的测定方法 |
Non-Patent Citations (2)
Title |
---|
无.黄芪当归阿胶口服液.《https://baike.baidu.com/history/%E9%BB%84%E8%8A%AA%E5%BD%93%E5%BD%92%E9%98%BF%E8%83%B6%E5%8F%A3%E6%9C%8D%E6%B6%B2/5401706/117002207》.2017, * |
黄芪当归阿胶口服液;无;《https://baike.baidu.com/history/%E9%BB%84%E8%8A%AA%E5%BD%93%E5%BD%92%E9%98%BF%E8%83%B6%E5%8F%A3%E6%9C%8D%E6%B6%B2/5401706/117002207》;20170301;第1页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107929420A (zh) | 2018-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107929420B (zh) | 改善人体气血功能和提高免疫力的中药组合物和检测方法 | |
CN104840934A (zh) | 一种预防和治疗仔猪腹泻的中药组合及制备方法 | |
CN101524469B (zh) | 一种治疗充血性心力衰竭的中药复方制剂及其制备方法 | |
CN105688160A (zh) | 一种中药组合物在制备治疗日光性皮炎药物中的用途 | |
CN104208581A (zh) | 一种预防酒精肝的五味子保健口服液及其制备方法 | |
CN109718303A (zh) | 提高女性卵巢功能养颜美容改善女性皮肤的中药组合物 | |
CN101524470A (zh) | 一种防治心血管疾病支架再狭窄的中药制剂及制备方法 | |
CN102940808A (zh) | 一种用于治疗肺癌的组方药物及制备方法 | |
CN102258628A (zh) | 一种具有促进排铅作用的中药组合物 | |
CN106109521A (zh) | 一种三七口服液 | |
CN109718304A (zh) | 改善人体心脑血管功能微循环及预防血栓的中药组合物 | |
CN116138455A (zh) | 三七多糖提取物及其在制备抗疲劳产品中的应用 | |
CN116173176A (zh) | 一种抗疲劳的中药组合物及其制备方法 | |
CN109771510A (zh) | 调节人体精气神和阴阳平衡的中药组合物和制备工艺 | |
CN104825864A (zh) | 对放疗具有增效作用的保健药膳及制备方法 | |
CN109718305A (zh) | 改善人体气血功能提高耐缺氧延缓衰老的中药组合物 | |
CN111084878A (zh) | 一种用于肺及呼吸系统疾病的生物医药、医用全营养食品及制备方法 | |
CN110898195A (zh) | 一种调理脑中风的中药食疗制品及其制备方法 | |
CN109731045A (zh) | 用于抑制肿瘤细胞生长预防治疗癌症的中药组合物 | |
CN112494614A (zh) | 一种木瓜百药组合防治癌病的中药配方 | |
CN104857121A (zh) | 一种治疗高血脂症的药物组合物及其应用 | |
CN109718302A (zh) | 治疗调节和延迟女性更年期综合征的中药组合物 | |
CN109731046A (zh) | 改善人体肾功能增强人体肾气的中药组合物的中药组合物 | |
CN114191532B (zh) | 一种降尿酸组合物、其制备方法及应用 | |
CN102772665B (zh) | 一种治疗阴虚内热型病毒性心肌炎的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Traditional Chinese medicine composition and detection method for improving human Qi and blood function and immunity Effective date of registration: 20220601 Granted publication date: 20210119 Pledgee: Zhangshu Shunyin Village Bank Co.,Ltd. Pledgor: JIANGXI TIANYUAN PHARMACEUTICAL CO.,LTD. Registration number: Y2022980006899 |